Publications by authors named "Joseph Merola"

Claim this Profile
I
Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab.
Andrew Blauvelt, Raj Chovatiya, Joseph F Merola, Stephan Weidinger, Ken Igawa

J Eur Acad Dermatol Venereol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Report of the IDEOM Meeting Adjacent to the GRAPPA 2024 Annual Meeting.
Sarah Romanelli, Beth Childs, Vibeke Strand, April W Armstrong, Lourdes M Perez-Chada, Joseph F Merola

J Rheumatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial.
Iain B McInnes, Laura C Coates, Philip J Mease, Alexis Ogdie, Arthur Kavanaugh, Joseph F Merola

Nat Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association of coronary artery disease by coronary CT angiography & cardiovascular outcomes in Psoriatic disease.
Jonathan A Aun, Daniel M Huck, Stephanie A Besser, Arthur Shiyovich, Milena Petranovic, Joseph Merola

Am J Prev Cardiol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With Guselkumab.
William Tillett, Laura C Coates, Marijn Vis, Miriam Zimmermann, Karissa Lozenski, Joseph F Merola

J Rheumatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Report From the 2024 International Dermatology Outcome Measures (IDEOM) Annual Meeting.
Sarah Romanelli, Gretchen D Ball, Arianna J Zhang, Christina Asare, Audrey Hao, Joseph F Merola

J Drugs Dermatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis.
Joseph F Merola, Lyn Guenther, Charles Lynde, Kim A Papp, Lawrence Charles Parish

J Eur Acad Dermatol Venereol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year.
Diamant Thaçi, Akihiko Asahina, Wolf-Henning Boehncke, Alice B Gottlieb, Mark Lebwohl, Joseph F Merola

Dermatol Ther (Heidelb)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic Arthritis.
Alexander Wu, Arianna Zhang, Yujia Guo, Jialiang Liu, Donghan M Yang, Joseph F Merola

JAMA Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies.
Joseph F Merola, Richard B Warren, Diamant Thaçi, Kenneth B Gordon, Emi Nishida

Am J Clin Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining "Flares" in Atopic Dermatitis: A Narrative Review.
Joseph F Merola, Stephan Weidinger, Sally Y Tan, Kassim Rahawi, Cori Gray

Am J Clin Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors.
Philip J Mease, Jessica A Walsh, Timothy P Fitzgerald, Soumya D Chakravarty, Elizabeth Adamson, Joseph F Merola

Rheumatol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors.
Andrew Blauvelt, Bruce E Strober, Guy S Eakin, Leah McCormick Howard, Christy Langan, Joseph F Merola

J Am Acad Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors.
Philip J Mease, Jessica A Walsh, Timothy P Fitzgerald, Soumya D Chakravarty, Elizabeth Adamson, Joseph F Merola

Adv Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single Cell Analysis of pBMCs of Psoriasis patients reveals distinct CD4+ T cell phenotypes associated with response to IL-23 blockade.
Kathryne E Marks, Anina Sun, Ifeoluwakiisi Adejoorin, Lourdes Perez Chada, Anna Perillo, Joseph F Merola

bioRxiv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The obesity-inflammation axis in psoriatic disease: mechanisms and therapeutic strategies.
Rebecca H Haberman, Alexis Ogdie, Joseph F Merola, Jose U Scher, Lihi Eder

Nat Rev Rheumatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and Prognostic Value of Incidentally Detected Coronary Artery Calcium Using Artificial Intelligence Among Individuals With Immune-Mediated Inflammatory Diseases.
Brittany N Weber, David W Biery, Milena Petranovic, Stephanie A Besser, Daniel M Huck, Joseph Merola

JACC Cardiovasc Imaging· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 4 D's of psoriasis disparities in patients with skin of color: A letter to the editor.
Beth A Childs, Arianna J Zhang, Andrew F Alexis, Joseph F Merola

J Am Acad Dermatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From the Masterclasses in Dermatology 2025 Meeting: Practical Approaches to Cutaneous and Systemic Lupus for Dermatologists.
Beth Childs, Joseph F Merola

J Clin Aesthet Dermatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hidradenitis Suppurativa Patients Experience a Significant Musculoskeletal Symptom Burden: A Quality Improvement Initiative Using the IDEOM MSK-Q.
Sarah Romanelli, Gretchen D Ball, Hassan Hamade, Mark Taliercio, Zachary Levy, Joseph F Merola

J Clin Aesthet Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Therapeutic Targets in the Management of Psoriatic Disease.
Beth A Childs, Joseph F Merola

Rheum Dis Clin North Am· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in US patients with psoriatic arthritis: Persistence, patient characteristics associated with discontinuation, and dosing patterns.
Joseph F Merola, Sarah Welby, Helena Roque, Jie Song, Olga Pilipczuk

J Manag Care Spec Pharm· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Streamlining Psoriatic Arthritis Screening and Management Using the IDEOM Clinical Framework: A Quality Improvement Initiative.
Sarah Romanelli, Gretchen D Ball, Hassan Hamade, Melissa P Zundell, Sangyoon Shin, Joseph F Merola

J Drugs Dermatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site Involvement.
Linda Stein Gold, Alice B Gottlieb, April W Armstrong, Theodore Alkousakis, Robert Bissonnette, Joseph F Merola

Br J Dermatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gaps in Documentation of Psoriatic Domains in General Rheumatologic Practices Compared to Rheumatology-Dermatology Combined Clinics.
Alexandra Lauren Rice, Sarah Gillespie, Nikhil Sai, Soumya M Reddy, Joseph F Merola

J Psoriasis Psoriatic Arthritis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis